Probi AB (PROB):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Probi AB (PROB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10145
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:45
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スウェーデン
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Probi AB (Probi) is a biotechnology company develops, produces and markets probiotics. The company offers licenses for its technology and sells finished products in bulk. It focuses on products for the improvement of gastrointestinal health and immune system. It distributes its products to leading food, health-product and pharmaceutical companies in the functional food and consumer healthcare segments. Probi markets its products through four different platforms: Probi Premium, Probi Select, Probi LiveBac and Probi Bio-tract. The company has operational presence in Sweden, Rest of Europe, North America and Rest of world. Probi is headquartered in Lund, Sweden.

Probi AB (PROB) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Probi AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Probi AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Probi AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Probi AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Probi AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Probi AB, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Probi Enters into Research Agreement with Wageningen University 11
Probi Enters into Co-Marketing Agreement with Pharmavite 12
Probi Enters Into Distribution Agreement With Dongkook Pharma 13
Probi Enters Into Agreement With BiO-LiFE Marketing For Probiotic Product 14
Symrise Enters Into R&D Agreement With Probi For Probiotic Products 15
Probi Enters Into Co-Marketing Agreement With Vifor Pharma 16
Probi Enters Into Distribution Agreement With Alvogen 17
USV Enters Into Distribution Agreement With Probi For Vibact IBS 18
Licensing Agreements 19
Ipsen Enters into Licensing Agreement with Probi 19
Acquisition 20
Symrise Completes Acquisition Of Additional 3.53% Stake In Probi 20
Probi AB – Key Competitors 21
Probi AB – Key Employees 22
Probi AB – Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Recent Developments 24
Financial Announcements 24
Aug 13, 2018: Q2 2018: Regained business momentum and strong margin improvement 24
Oct 25, 2017: Probi: Interim report Q1-Q3 2017 25
May 04, 2017: Probi continues on its successful growth path 29
Jan 10, 2017: Probi – Strong Growth in net Sales and Operating Profit in the Fourth Quarter 32
Corporate Communications 33
Oct 01, 2018: Probi names Tom Ronnlund as new CEO 33
Jul 19, 2018: Probi announces resignation of Jorn Andreas as CFO 34
Mar 14, 2018: Probi Appoints Ole Sogaard Andersen As Interim CEO 35
Feb 14, 2017: Probi appoints Jorn Andreas as new CFO 36
Government and Public Interest 37
Sep 11, 2017: New clinical study shows that Probi’s probiotics support the immune system and may delay the onset of gluten intolerance in children 37
Product News 38
Feb 06, 2018: Probi’s largest clinical trial confirms the immune enhancing impact of Probi Defendum and sheds new light on the mechanism 38
Other Significant Developments 39
Apr 11, 2018: Probi enters the bone health area – a new area for probiotics 39
Jan 25, 2018: Probi: Q4 – 2017 Year-End Report 40
Appendix 45
Methodology 45
About GlobalData 45
Contact Us 45
Disclaimer 45

List of Tables
Probi AB, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Probi AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Probi AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Probi AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Probi AB, Deals By Therapy Area, 2012 to YTD 2018 9
Probi AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Probi Enters into Research Agreement with Wageningen University 11
Probi Enters into Co-Marketing Agreement with Pharmavite 12
Probi Enters Into Distribution Agreement With Dongkook Pharma 13
Probi Enters Into Agreement With BiO-LiFE Marketing For Probiotic Product 14
Symrise Enters Into R&D Agreement With Probi For Probiotic Products 15
Probi Enters Into Co-Marketing Agreement With Vifor Pharma 16
Probi Enters Into Distribution Agreement With Alvogen 17
USV Enters Into Distribution Agreement With Probi For Vibact IBS 18
Ipsen Enters into Licensing Agreement with Probi 19
Symrise Completes Acquisition Of Additional 3.53% Stake In Probi 20
Probi AB, Key Competitors 21
Probi AB, Key Employees 22
Probi AB, Subsidiaries 23

List of Figures
Probi AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Probi AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Probi AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Probi AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Probi AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Probi AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Probi AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Probi AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Probi AB (PROB):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • B&N Bank (Joint-Stock Company):企業の戦略・SWOT・財務情報
    B&N Bank (Joint-Stock Company) - Strategy, SWOT and Corporate Finance Report Summary B&N Bank (Joint-Stock Company) - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Commerce Resources Corp (CCE):企業の財務・戦略的SWOT分析
    Summary Commerce Resources Corp (Commerce Resources) is a minerals exploration and development company that explores for deposits of rare earth elements and rare metals. The company acquires, explores, produces, develops, evaluates mineral resource properties, and others. It explores for niobium and …
  • eResearchTechnology Inc:企業の戦略的SWOT分析
    eResearchTechnology Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Sumitomo Heavy Industries Ltd (6302)
    Sumitomo Heavy Industries Ltd (6302) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company
  • Hyundai Motor Co (005380)-エネルギー分野:企業M&A・提携分析
    Summary Hyundai Motor Company (Hyundai) is a global manufacturer of automobiles, which designs, develops and manufactures passenger and heavy duty automobiles and relevant parts. The company manufactures passenger cars under various brand names such as Centennial, Genesis, Veloster, Azera, Sonata, i …
  • Valener Inc (VNR):企業の戦略的SWOT分析
    Valener Inc (VNR) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Radico Khaitan Ltd.:企業の戦略・SWOT・財務分析
    Radico Khaitan Ltd. - Strategy, SWOT and Corporate Finance Report Summary Radico Khaitan Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • J & J Snack Foods Corp:企業の戦略・SWOT・財務情報
    J & J Snack Foods Corp - Strategy, SWOT and Corporate Finance Report Summary J & J Snack Foods Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Showa Sangyo Co., Ltd.:企業の戦略・SWOT・財務情報
    Showa Sangyo Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Showa Sangyo Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Groupe Guillin SA:企業の戦略・SWOT・財務情報
    Groupe Guillin SA - Strategy, SWOT and Corporate Finance Report Summary Groupe Guillin SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • KKR & Co. L.P.:企業の戦略・SWOT・財務情報
    KKR & Co. L.P. - Strategy, SWOT and Corporate Finance Report Summary KKR & Co. L.P. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Terracon Consultants Inc:企業のM&A・事業提携・投資動向
    Terracon Consultants Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Terracon Consultants Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisiti …
  • Theranyx Sarl:製薬・医療:M&Aディール及び事業提携情報
    Summary Theranyx Sarl is a bio technology company that develops novel therapeutic drugs and solutions to treat cancer. The company’s main line business involved in generation of functional antibodies to target GPCRs and ion channel receptors. Its antibodies named as Therabodies has scope in target v …
  • Housing Development & Infrastructure Ltd:企業の戦略・SWOT・財務情報
    Housing Development & Infrastructure Ltd - Strategy, SWOT and Corporate Finance Report Summary Housing Development & Infrastructure Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • MiMedx Group Inc (MDXG):企業の財務・戦略的SWOT分析
    Summary MiMedx Group Inc (MiMedx) is a biopharmaceutical company that develops, manufactures and markets regenerative biologics utilizing human placental allografts. The company provides products such as amniotic membrane, umbilical cord, placental ECM and amniotic fluid. It utilizes proprietary pur …
  • Keepmoat Ltd:企業の戦略的SWOT分析
    Keepmoat Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Mobile Telesystems:企業の戦略・SWOT・財務情報
    Mobile Telesystems - Strategy, SWOT and Corporate Finance Report Summary Mobile Telesystems - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • The GPT Group:企業の戦略・SWOT・財務情報
    The GPT Group - Strategy, SWOT and Corporate Finance Report Summary The GPT Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • OJSC Dixy Group:企業の戦略・SWOT・財務情報
    OJSC Dixy Group - Strategy, SWOT and Corporate Finance Report Summary OJSC Dixy Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Spero Therapeutics Inc (SPRO):製薬・医療:M&Aディール及び事業提携情報
    Summary Spero Therapeutics Inc. (Spero) is a clinical-stage biopharmaceutical company. It is engaged in developing, identifying and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections. Its product pipeline includes SPR994 oral gram-negative program, SPR741and SPR206 …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆